Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common diseases, ...
Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
GlobalData on MSN22h
DMTs are major clinical research focus for Parkinson’s disease, analysis showsAnalysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...
Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...
In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...
Nir Giladi from TAU’s Faculty of Medical and Health Sciences and the Tel Aviv Sourasky Medical Center, as well as other researchers from TAU and the University of Haifa. The study was backed by the ...
GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...
GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
There’s still a lot we don’t know about how Parkinson’s disease develops. But one lifestyle intervention already has strong evidence behind it.
Experts made the discovery after analysing hours of YouTube footage of celebrities with the disease - and it paves the way ...
A Risky Business: Why Do Some Parkinson's Disease Treatments Affect Decision Making? Sep. 24, 2024 — Parkinson's disease, a debilitating nervous system disorder, is treated with medications that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback